Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma
暂无分享,去创建一个
Clive Taylor | Henrik Winther | Xiaoling Zhang | H. Inzunza | J. Cogswell | E. Oroudjev | B. Spaulding | J. Novotny | M. Jansson | Therese Phillips | Molly M. Millett | Xiaoling Zhang | Malinka Jansson | Rachel Cleveland | Pauline Simmons | Gregory Cherryholmes | Josette Carnahan | Josette William | Betsy Spaulding | Ilana R. Satnick | H. David Inzunza | John Cogswell | James Novotny | Emin Oroudjev | H. Winther | Josette William | J. Carnahan | G. Cherryholmes | T. Phillips | P. Simmons | C. Taylor | Ilana Satnick | R. Cleveland
[1] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[2] G. Freeman,et al. PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.
[3] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[4] Richard Pazdur,et al. An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies , 2016, Clinical Cancer Research.
[5] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[6] J. Allison,et al. Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.
[7] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[8] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[9] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[10] Xiaoling Zhang,et al. Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer , 2015, Applied immunohistochemistry & molecular morphology : AIMM.
[11] M. Dolled-Filhart,et al. Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer , 2016, Applied immunohistochemistry & molecular morphology : AIMM.
[12] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[13] Gideon Blumenthal,et al. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy , 2016, The oncologist.
[14] Mike Mcmullen. Agilent Technologies , 2017 .
[15] G. Zhu,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[16] M. Tiemann,et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas , 2016, Modern Pathology.
[17] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[18] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[19] S. Álvarez,et al. 1059PPD-L1 Detection and Assay Performance in Squamous Cell Carcinoma of the Head and Neck Using PD-L1 IHC 28-8 pharmDx , 2017 .